Anne Li September 16th, 2017 firstname.lastname@example.org
A drug that exploits genetic weaknesses in cancer cells can delay some advanced ovarian cancers from getting worse, according to unpublished clinical trial results. Findings from the phase 3 ARIEL3 trial showed that rucaparib (Rubraca) – a type of PARP inhibitor– boosted the length of time before patients’ disease returned by many months. Professor Jonathan Ledermann, who led the study at the Cancer Research UK and UCL Cancer Trials Centre, described the findings as a “very important step forward for women with advanced ovarian cancer”.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-09-08-targeted-drug-helps-keep-some-advanced-ovarian-cancers-at-bay